Objective To compare the clinical pregnancy outcomes of tamoxifen(TAM),TAM combined with intrauterine perfusion of platelet-rich plasma(PRP),and hormone replacement therapy(HRT)combined with intrauterine perfusion of PRP for frozen-thawed embryo transfer(FET)in patients with thin endometrium.Methods A retrospective analysis was performed on clinical data of 321 patients with thin endometrium(endome-trial thickness≤7 mm in previous cycles)who underwent FET at the Reproductive Medicine Center of Guangdong Provincial Reproductive Hospital from January 2023 to April 2025.According to the treatment protocols,the patients were divided into three groups:TAM group(Group A,n=98),TAM+PRP group(Group B,n=91),and HRT+PRP group(Group C,n=132).General information,endometrial thickness on the conversion day before and after treatment,clinical pregnancy outcomes,andcosts of endometrial preparation treatment were com-pared among the three groups.Results There were no significant differences in age,duration of infertility,type of infertility,anti-Müllerian hormone(AMH)level,basal follicle-stimulating hormone(FSH)among the three groups(P>0.05).After treatment,there were no significant differences in endometrial thickness on the conversion day or the extent of increase among the three groups(P>0.05).The clinical pregnancy rates in Group A,Group B,and Group C were 56.1%,51.6%,and 43.2%respectively,with a significant difference(P=0.011);the embryo implantation rates were 43.6%,45.5%,and 34.6%respectively,showing a significant difference(P=0.019).The early abortion rate in Group A(3.64%)was significantly lower than that in Group C(15.79%)(P<0.01).In terms of treatment cost of endometrial preparation treatment,the cost in Group A(676.5±494.5 Yuan)was significantly lower than that in Group B(2 401.2±764.2 Yuan)and Group C(3 093.8±758.3 Yuan)(P<0.01).Conclusion In FET cycles for patients with thin endometrium,the clinical outcomes of TAM,TAM+PRP and HRT+PRP are comparable,and TAM demonstrates advantages in terms of a lower early miscarrage rate and better cost-effectiveness,thus serving as an option for endometrial preparation in patients with thin endometrium.

Objective To compare the clinical pregnancy outcomes of tamoxifen(TAM),TAM combined with intrauterine perfusion of platelet-rich plasma(PRP),and hormone replacement therapy(HRT)combined with intrauterine perfusion of PRP for frozen-thawed embryo transfer(FET)in patients with thin endometrium.Methods A retrospective analysis was performed on clinical data of 321 patients with thin endometrium(endome-trial thickness≤7 mm in previous cycles)who underwent FET at the Reproductive Medicine Center of Guangdong Provincial Reproductive Hospital from January 2023 to April 2025.According to the treatment protocols,the patients were divided into three groups:TAM group(Group A,n=98),TAM+PRP group(Group B,n=91),and HRT+PRP group(Group C,n=132).General information,endometrial thickness on the conversion day before and after treatment,clinical pregnancy outcomes,andcosts of endometrial preparation treatment were com-pared among the three groups.Results There were no significant differences in age,duration of infertility,type of infertility,anti-Müllerian hormone(AMH)level,basal follicle-stimulating hormone(FSH)among the three groups(P>0.05).After treatment,there were no significant differences in endometrial thickness on the conversion day or the extent of increase among the three groups(P>0.05).The clinical pregnancy rates in Group A,Group B,and Group C were 56.1%,51.6%,and 43.2%respectively,with a significant difference(P=0.011);the embryo implantation rates were 43.6%,45.5%,and 34.6%respectively,showing a significant difference(P=0.019).The early abortion rate in Group A(3.64%)was significantly lower than that in Group C(15.79%)(P<0.01).In terms of treatment cost of endometrial preparation treatment,the cost in Group A(676.5±494.5 Yuan)was significantly lower than that in Group B(2 401.2±764.2 Yuan)and Group C(3 093.8±758.3 Yuan)(P<0.01).Conclusion In FET cycles for patients with thin endometrium,the clinical outcomes of TAM,TAM+PRP and HRT+PRP are comparable,and TAM demonstrates advantages in terms of a lower early miscarrage rate and better cost-effectiveness,thus serving as an option for endometrial preparation in patients with thin endometrium.

Objective:To evaluate the effect of oral Aescuven forte on the incidence and severity of ovarian hyperstimulation syndrome (OHSS).Methods:A total of 100 patients who cancelled transplantation after oocyte retrieval for in vitro fertilization-embryo transfer assisted reproduction due to high risk of OHSS between February 2018 and October 2019 in Reproductive Medicine Research Center, the Sixth Affiliated Hospital, Sun Yat-Sen University were randomized into two groups in this prospective randomized controlled trial. The patients in experimental group (50 cases) received 300 mg, bid of Aescuven forte orally for 10 d after oocyte retrieval, while control group (50 cases) did not receive Aescuven forte; otherwise, both groups underwent the same treatments. The incidence rate and severity of OHSS were compared between the two groups. Results:No significant differences were found in variables such as age, body mass index (BMI), anti-Müllerian hormone (AMH) level, total dosage of gonadotropin (Gn) used, and the number of retrieved oocytes between the two groups ( P>0.05). The incidence rate of moderate to severe OHSS in experimental group and control group was 4.00% (2/50) and 18.00% (9/50), respectively, with a statistically significant difference ( P=0.025). Control group included 3 cases of paracentesis due to ascites, while experimental group did not include any cases of paracentesis or severe OHSS. Conclusion:Oral administration of Aescuven forte effectively prevent the incidence of moderate to severe OHSS in high-risk patients and reduced the severity of OHSS.

Objective:To evaluate the effect of oral Aescuven forte on the incidence and severity of ovarian hyperstimulation syndrome (OHSS).Methods:A total of 100 patients who cancelled transplantation after oocyte retrieval for in vitro fertilization-embryo transfer assisted reproduction due to high risk of OHSS between February 2018 and October 2019 in Reproductive Medicine Research Center, the Sixth Affiliated Hospital, Sun Yat-Sen University were randomized into two groups in this prospective randomized controlled trial. The patients in experimental group (50 cases) received 300 mg, bid of Aescuven forte orally for 10 d after oocyte retrieval, while control group (50 cases) did not receive Aescuven forte; otherwise, both groups underwent the same treatments. The incidence rate and severity of OHSS were compared between the two groups. Results:No significant differences were found in variables such as age, body mass index (BMI), anti-Müllerian hormone (AMH) level, total dosage of gonadotropin (Gn) used, and the number of retrieved oocytes between the two groups ( P>0.05). The incidence rate of moderate to severe OHSS in experimental group and control group was 4.00% (2/50) and 18.00% (9/50), respectively, with a statistically significant difference ( P=0.025). Control group included 3 cases of paracentesis due to ascites, while experimental group did not include any cases of paracentesis or severe OHSS. Conclusion:Oral administration of Aescuven forte effectively prevent the incidence of moderate to severe OHSS in high-risk patients and reduced the severity of OHSS.